Mabpharm Limited released its earnings results on Mar 26, 2025. The company reported -HK$0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.008.

Is Mabpharm Limited overvalued?

According to Wall Street analysts Mabpharm Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Mabpharm Limited pay dividends?

Mabpharm Limited does not currently pay dividends.

What is Mabpharm Limited’s EPS estimate?

Mabpharm Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Mabpharm Limited have?

Mabpharm Limited has 4,124,080,000 shares outstanding.

What happened to Mabpharm Limited’s price movement after its last earnings report?

Mabpharm Limited reported an EPS of -HK$0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.091%.

Which hedge fund is a major shareholder of Mabpharm Limited?

Currently, no hedge funds are holding shares in HK:2181

---

Mabpharm Limited Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

-86.56%

Trailing 12-Months

Asset Growth

-5.09%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mabpharm Limited

Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for allergic diseases, cancers, and autoimmune diseases in China. Its products under the Phase III clinical trial include CMAB007, a recombinant humanized anti-IgE monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for moderate to severe active rheumatoid arthritis; and CMAB807 for osteoporosis indications. The company is also developing CMAB819 that is in Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X for the treatment of tumor bone metastasis; and CMAB809 that is in Phase I clinical trial for the treatment of HER2 overexpressing breast cancer and metastatic gastric cancer. In addition, its products under the pre-clinical stage include CMAB810 for the treatment of breast cancer; CMAB816 for the treatment of periodic fever syndrome, lung cancer, and systemic juvenile idiopathic arthritis; CMAB017 for the treatment of KRAS wild-type colorectal cancer; CMAB015, a biosimilar candidate for secukinumab to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; CMAB018, a biosimilar candidate for mepolizumab, for the treatment of asthma and eosinophilic granulomatous polyangiitis; and CMAB022 for the treatment of inflammatory diseases. The company also involved in research and development, technical consulting, technology transfer, and technical services of biological products, diagnostic reagents, chemical biological reagents, and drugs. The company was incorporated in 2018 and is headquartered in Taizhou, the People's Republic of China.

---